Adicet Bio Future Growth
Future criteria checks 2/6
Adicet Bio is forecast to grow earnings and revenue by 6.7% and 79.7% per annum respectively while EPS is expected to grow by 9.5% per annum.
Key information
6.7%
Earnings growth rate
9.5%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 79.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12
Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -133 | -69 | -123 | 7 |
| 12/31/2025 | 3 | -127 | -81 | -107 | 8 |
| 12/31/2024 | N/A | -121 | -100 | -97 | 8 |
| 9/30/2024 | N/A | -118 | -93 | -92 | N/A |
| 6/30/2024 | N/A | -137 | -93 | -91 | N/A |
| 3/31/2024 | N/A | -140 | -95 | -92 | N/A |
| 12/31/2023 | N/A | -143 | -98 | -94 | N/A |
| 9/30/2023 | N/A | -143 | -100 | -89 | N/A |
| 6/30/2023 | N/A | -115 | -98 | -83 | N/A |
| 3/31/2023 | N/A | -105 | -89 | -73 | N/A |
| 12/31/2022 | 25 | -70 | -62 | -45 | N/A |
| 9/30/2022 | 30 | -56 | -53 | -39 | N/A |
| 6/30/2022 | 34 | -48 | -49 | -34 | N/A |
| 3/31/2022 | 39 | -36 | -47 | -32 | N/A |
| 12/31/2021 | 10 | -62 | -64 | -51 | N/A |
| 9/30/2021 | 10 | -55 | -61 | -51 | N/A |
| 6/30/2021 | 9 | -56 | -52 | -49 | N/A |
| 3/31/2021 | 12 | -54 | -50 | -48 | N/A |
| 12/31/2020 | 18 | -37 | -43 | -42 | N/A |
| 9/30/2020 | 14 | -34 | -37 | -35 | N/A |
| 6/30/2020 | 4 | -34 | -36 | -35 | N/A |
| 3/31/2020 | 0 | -28 | -30 | -29 | N/A |
| 12/31/2019 | 1 | -28 | -29 | -28 | N/A |
| 12/31/2018 | 8 | -9 | -19 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACET is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACET is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACET is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACET's revenue (79.7% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: ACET's revenue (79.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACET's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 13:06 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adicet Bio, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |
| Yatin Suneja | Guggenheim Securities, LLC |